Compare RMD & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMD | RVMD |
|---|---|---|
| Founded | 1989 | 2014 |
| Country | United States | United States |
| Employees | 10600 | 883 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.4B | 30.1B |
| IPO Year | N/A | N/A |
| Metric | RMD | RVMD |
|---|---|---|
| Price | $210.27 | $189.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 19 |
| Target Price | ★ $292.56 | $140.84 |
| AVG Volume (30 Days) | 1.3M | ★ 1.8M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.60 | N/A |
| Revenue Next Year | $7.41 | $533.02 |
| P/E Ratio | $25.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $180.27 | $34.00 |
| 52 Week High | $293.81 | $194.56 |
| Indicator | RMD | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 57.00 | 55.41 |
| Support Level | $198.63 | $176.00 |
| Resistance Level | $211.74 | $193.83 |
| Average True Range (ATR) | 5.20 | 7.45 |
| MACD | 1.35 | -0.96 |
| Stochastic Oscillator | 76.99 | 58.24 |
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.